申请人:Merrell Dow Pharmaceuticals Inc.
公开号:US04699928A1
公开(公告)日:1987-10-13
Fluoroallylamine derivatives of the following Formula I are novel MAO-inhibitors and at low dose levels selectively inhibit MAO-B: ##STR1## wherein: R.sub.1 and R.sub.2 independently represent hydrogen, chlorine or fluroine; R.sub.3 represents hydrogen or (C.sub.1 -C.sub.4)alkyl; and X represents oxygen or sulfur. They are useful for the treatment of depression and, co-administered with L-dopa, in the treatment of Parkinsonism.
以下的化学式I中的氟烯丙胺衍生物是新型的MAO抑制剂,在低剂量水平上选择性地抑制MAO-B:其中:R.sub.1和R.sub.2独立地代表氢、氯或氟;R.sub.3代表氢或(C.sub.1 -C.sub.4)烷基;X代表氧或硫。它们用于治疗抑郁症,并且与L-多巴一起联合使用,可用于治疗帕金森病。